Peptide-drug conjugates for tumor targeted diagnosis and treatment
10.16438/j.0513-4870.2022-1053
- VernacularTitle:多肽-药物键合物用于肿瘤靶向诊疗
- Author:
Ying CHEN
;
Rong-rong ZHENG
;
Shi-ying LI
- Publication Type:Research Article
- Keywords:
peptide;
linker;
anti-cancer agent;
tumor targeting;
rug delivery system
- From:
Acta Pharmaceutica Sinica
2023;58(8):2341-2352
- CountryChina
- Language:Chinese
-
Abstract:
Cancer is still one of the major diseases threatening human life and health. At present, how to achieve precise diagnosis and treatment of tumors is the biggest challenge in cancer treatment. Prodrugs use the tumor specificity of targeting molecules to deliver anticancer drugs to tumor sites, which can effectively improve drug bioavailability, therapeutic efficacy and safety, and are currently a hot spot in the research and development of anticancer drugs. The targeting molecules of prodrugs mainly include nucleic acid aptamers, polymers, antibodies, polypeptides, etc. Among them, polypeptides have the advantages of good biocompatibility, controllable degradation performance, high in vivo responsiveness, and simple and easy preparation methods, and are widely used. It is used to construct peptide-drug conjugates (PDC) prodrugs to achieve targeted therapy of tumors. In recent years, with the development of phage peptide library technology and peptide standard solid-phase synthesis technology, more and more targeted peptides have been discovered and effectively synthesized and modified, providing strong support for the development of PDC. This review briefly introduces the types and functions of functional peptides and linkers in PDC, and discusses the application of PDC in chemotherapy, immunotherapy and photodynamic therapy in tumor targeted diagnosis and treatment, and finally summarizes the difficulties faced by PDC drug development.
